Psychedelic medicines may represent a new frontier for end-of-life care, as well as psychiatric treatment. While these substances including LSD, MDMA, psilocybin and ketamine, among others remain illegal, grass roots support for decriminalization or medical use is growing. Meanwhile, venture capitalists and other investors are spending billions to get on the ground floor of what could become a new health care industry.
Much of the research and discussion on medical use of psychedelics has focused on care at the end of life. Interest in the potential medical benefits of these substances became widespread during the 1960s, but research all but stopped after they were criminalized through federal legislation in 1970. The first inklings of a resurgence began in the late 1990s, and momentum has picked up during the last decade.
The evidence is just so compelling, and we have very little in terms of tools in our medical bag to be able to help people who are suffering from existential distress, anxiety and depression related to a serious illness diagnosis, Shoshana Ungerleider, M.D., internist at Crossover Health in San Francisco, founder of the organization End Well,said. We want people to be able to live fully until they die. If psychedelics given in a controlled therapeutic environment with trained clinicians who can help them do that, then these medicines should be more widely available.
End Well recently produced a conference on the subject of psychedelic medicine for dying patients.
The body of scientific literature on psychedelics for dying patients continues to advance. Johns Hopkins Medicine in 2019 established a Center for Psychedelic and Consciousness Research backed by $17 million in grants.
Researchers have identified a number of clinical benefits, including reduction of anxiety, depression and improved acceptance of mortality, according to a 2019 literature review in the journal Current Oncology. The paper cited studies indicating that the most commonly used psychedelic drugs have no tissue toxicity, do not interfere with liver function, have few interactions with other medications and carry no long-term physical effects. Common side effects tend to be short in duration, such as nausea and vomiting or disruption of visual or spatial orientation.
Patients who use psychedelic medicines often report what researchers commonly describe as a mystical experience, involving a feeling of unity, sacredness, deeply-felt positive mood, transcendence of space and time, and other effects that study participants found difficult to verbalize, according to the Current Oncology paper.
This can be transformative for people with anyone who is wracked with trauma, grief, loss or extreme states of suffering, Sunil Aggarwal, M.D., co-founder, co-director and practitioner at the Advanced Integrative Medical Science (AIMS) Institute in Seattle, told Hospice News. Theres also evidence that these substances can also reduce physical pain.
Aggarwal is a board-certified hospice and palliative care physician and a past chair of the American Academy of Hospice and Palliative Medicine (AAHPM).
All psychedelics are illegal at the federal level and in most states. Oregon in 2020 became the first in the union to remove criminal penalties for all illegal drugs and is now in the process of establishing the nations first state-licensed psilocybin-assisted therapy system.
More action has been happening at the local level, with communities such as Washington, D.C., Denver, Ann Arbor, Mich., three Massachusetts cities, and Santa Cruz and Oakland in California voting to decriminalize some psychedelics and permit medical use. Some of these regions are now considering statewide decriminalization.
Connecticut and Texas each have laws on the books that created work groups to study the medical use of psilocybin, MDMA and ketamine. Legislatures in Hawaii, Iowa, Maine, Missouri, Vermont and New York state are currently mulling decriminalization or medical use bills.
In late July, Rep. Alexandria Ocasio-Cortez (D-N.Y.) reintroduced an amendment to remove federal barriers to research the therapeutic potential of psychedelic substances. The U.S. House of Representatives quickly shot down the legislation, though it garnered more support this round than the previous time it was introduced.
We quite a few years off from having enough trained therapists and a policy pathway for which these can be made more widely available in a controlled therapeutic setting, Ungerleider said. Theres just so much interest right now among patients and among family members to learn more about this. All health care professionals need to have an understanding of where were at with psychedelics.
Interest in psychedelics has transcended the research space and entered the business world. The familiar adage, follow the money, frequently provides good indicators of which way the wind is blowing.
The psychedelics industry is expected to bring in more than $6.85 billion by 2027, Forbes reported. Many of these investors are seeking to reproduce the lucrative results of the cannabis industry that emerged in the wake of legalization among a number of states. A recent report indicated that 36 states and four territories allow use of medical cannabis products, according to the National Conference of State Legislatures.
The largest investors in psychedelics include the venture capital firms Conscious Fund, Explorer Equity Group and Pala Santo. Earlier this year, Florida-based cannabis and psychedelics attorney Dustin Robinson co-founded Iter Investments, a new venture capital group focused on that sector.
A United Kingdom-based psychedelics-focused pharmaceutical company, Compass Pathways (NASDAQ: CMPS), went public in Sept. 2020 and is now worth an estimated $1.2 billion.
Theres a unique opportunity to be able to go ahead and develop and commercialize [psychedelics] to a much larger patient population, health care investor and venture capitalist Andrew Lee told Hospice News. Itll be interesting to see how natural pharmaceuticals might work. Theres the nonprofit, sacred path, the pharma path and the botanical drug sort of path. The most important thing is that this is another tool in the toolbox for treating a number of conditions.
Originally posted here:
- Study Finds 65% Of Americans With Mental Health Conditions Want Access To Psychedelics - Forbes - January 24th, 2022
- What are the potential risks of microdosing psychedelics? - Leafly - January 24th, 2022
- Trade To Black Podcast 20: Is the Selling In MSOS And Psychedelics Getting Overdone? A Frank Discussion - The Dales Report - January 24th, 2022
- Icebreakers with...MindMed CEO Rob Barrow - Morning Brew - January 24th, 2022
- Research in 60 Seconds: How Taking Psychedelics Can Be Therapeutic - UCF - January 24th, 2022
- TDRs Top 5 Psychedelic Developments For The Week Of January 17 - The Dales Report - January 24th, 2022
- The Psychedelics Series: The history and future of ketamine - The Cannabis Exchange - January 24th, 2022
- How 2021 became the year of psychedelics - and why 2022 is set to be even bigger - The Cannabis Exchange - January 24th, 2022
- Why Is Everyone Smoking Toad Venom? - What To Know About the Hallucinogenic Toad, DMT, Bufo - TownandCountrymag.com - January 24th, 2022
- Breaking Down Numinus Wellness Quarterly Results - The Dales Report - January 24th, 2022
- Ancient Latin American Empire Could Have Thrived Thanks to Psychedelic-Infused Beer - StreetInsider.com - January 24th, 2022
- Psychedelics can change humanity for the better. Its time ... - January 9th, 2022
- 'Microdosers' of LSD and magic mushrooms are wiser... - Daily Maverick - January 9th, 2022
- Core One Labs Now Also Working to Biosynthesize DMT and Receives License - Financial Post - January 9th, 2022
- NeonMind to Present at H.C. Wainwright Bioconnect Conference - Yahoo Finance - January 9th, 2022
- Magic mushroom companies are on the Nasdaq now. Thats a recipe for a bad trip - The Guardian - January 7th, 2022
- Psilocybin therapy options could expand in Hawaii | Hawai'i Public Radio - Hawaiipublicradio - January 7th, 2022
- From psychedelics to 'The Great Resignation' - wellness trends for 2022 - CapeTown ETC - January 7th, 2022
- Ketamine, Psilocybin and the Rise of Missouri Psychedelics - Riverfront Times - December 25th, 2021
- Animals That Eat Psychedelics And Enjoy The Trip - Benzinga - Benzinga - December 25th, 2021
- Bad Hug - The Cut - December 25th, 2021
- How Seeing God Might Be The Secret To The Most Cutting-Edge Mental Health Treatments - Forbes - December 25th, 2021
- Happy Holidays From The Dales Report Team - The Dales Report - December 25th, 2021
- GOP Lawmakers File Bills To Streamline Research Into Marijuana, Psychedelics And Other Schedule I Drugs - Marijuana Moment - December 22nd, 2021
- Meet Zappy Zapolin, The Psychedelic Concierge Who Turned Lamar Odom On To Ketamine - Forbes - December 22nd, 2021
- Numinus Wellness inc: Leading in the psychedelics race - Proactive Investors UK - December 22nd, 2021
- When Aldous Huxley Opened the Doors of Perception - The MIT Press Reader - December 22nd, 2021
- Kratom Attracts Investor Attention After Regulatory Win - Bloomberg - December 22nd, 2021
- Two esteemed doctors join CB Therapeutics in its exploration of innovative approaches to the production of novel psychedelics and cannabinoids so... - December 22nd, 2021
- Revenge travel and psychedelic retreats: The travel trends taking flight in 2022 - AsiaOne - December 22nd, 2021
- Cybin Awarded Notice of Allowance from US Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety... - December 15th, 2021
- TGA blocks bid to have MDMA, magic mushrooms used to treat mental health conditions - ABC News - December 15th, 2021
- PharmaTher Announces Positive Research Results for LSD Microneedle Patch - Yahoo Finance - December 15th, 2021
- MDMA could soon be used to treat PTSD according to physicians - Mixmag - December 15th, 2021
- MindMed Appoints Robert Barrow as Chief Executive Officer and Director - Yahoo Finance - December 15th, 2021
- MAPS and Wesana Health Resume Negotiations - GlobeNewswire - December 15th, 2021
- Sex, psychedelics and murderous impulses: Do we know too much about Will Smith? - The Independent - November 7th, 2021
- PharmaDrug commissions TIBI for advancing psychedelics program with analogue DMT formulation to cure eye diseases - Proactive Investors USA - November 7th, 2021
- I Have $1,000. Should I Invest In Cannabis, Crypto Or Psychedelics? - Benzinga - Benzinga - November 7th, 2021
- Detroit just decriminalized psychedelics and magic mushrooms. Heres what that means - PBS NewsHour - November 5th, 2021
- Psychedelics linked to lower risk of heart disease and diabetes - Medical News Today - November 5th, 2021
- The people turning to psychedelics on their deathbeds - The Independent - November 5th, 2021
- Psychedelic Therapy Is Hyped, But Its Not Risk-Free: How Therapy Abuse Can Retraumatize Clients - Forbes - November 5th, 2021
- Defeating Gambling Addiction: New Study Looks To Defy The Odds With Psychedelics - Forbes - November 5th, 2021
- This Psychedelics Unicorn's Stock Is Up 50% In One MonthBeating Bitcoin, Ethereum And Dogecoin - Benzing - Benzinga - November 5th, 2021
- This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop - Benzinga - November 5th, 2021
- Biglaw Associate Is Advocating For Therapeutic Use Of Psychedelics And The Firm Is Backing Him Up - Above the Law - November 5th, 2021
- Easthampton is the fourth city in Mass. to vote to decriminalize psychedelics - WBUR - October 24th, 2021
- There Could Be a Curious Link Between Psychedelics And Improved Heart Health - ScienceAlert - October 24th, 2021
- How Atai Is Transforming The Landscape Of Mental Health Using Psychedelics (Part 2) - Forbes - October 24th, 2021
- A recent history of therapeutic psychedelics - Toronto Life - October 24th, 2021
- New Research Hints at a Link Between Psychedelics and Improved Heart Health - The Swaddle - October 24th, 2021
- Why Ketamine-Assisted Therapy Has Gone Mainstream - Forbes - October 24th, 2021
- Ketamine and psilocybin, better known as party drugs, showing promise for treatment of mood disorders - CTV News - October 24th, 2021
- Recent progress in psychedelic therapies - Lexology - October 24th, 2021
- Miracles and medication: The new science of psychedelic drugs - Stuff.co.nz - October 24th, 2021
- UAB researcher granted federal funding for psilocybin and smoking study - The Mix - October 24th, 2021
- Yale researchers using psychedelics to find new treatments for depression - WTNH.com - September 17th, 2021
- Want Quick Exposure To The Psychedelics Sector? Check Out This New Active ETF - Benzinga - Benzinga - September 17th, 2021
- 5 things to know about the Ann Arbor psychedelic shroom fest - MLive.com - September 17th, 2021
- A Look At Psychedelics Stock PharmaTher And Its Recent Bull Run - Benzinga - Benzinga - September 17th, 2021
- Differentiated Approach in Psychedelics Boosts Confidence in Upcoming Clinical Trials for Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) -... - September 17th, 2021
- Psychedelics research and public education elevated by multiple gifts - UC Berkeley - September 16th, 2021
- Pain Awareness Month: Psychable Educates Patients on Transformative Power of Using Psychedelics as Medicine for Pain Treatment, Management and Healing... - September 16th, 2021
- $80 Million Granted to Research Psychedelic Properties of Ingesting Toad Venom - Newsweek - September 16th, 2021
- Psychedelic Use on the Rise As Gen Z Seeks To Enhance Connectedness - VICE UK - September 16th, 2021
- Phyto Partners Cannabis VC on Why He's Investing in Psychedelics - Business Insider - September 16th, 2021
- Detroit Voters Will Decide On Psychedelics Decriminalization Ballot Measure In November - Marijuana Moment - September 16th, 2021
- Seattle bid to decriminalize psychedelics could have profound effect on treating addiction - MyNorthwest.com - September 16th, 2021
- Post-9/11 vets go to Mexico to treat trauma with psychedelic - The San Diego Union-Tribune - September 16th, 2021
- Lobe Sciences to Participate at the Advances in Me... | INN - Investing News Network - September 16th, 2021
- Seattle is now in the process of legalizing psychedelics, heres what to know - Curiocity - September 16th, 2021
- World Suicide Prevention Day: Suicide Remains a Leading Global Cause of Death; Communities Across the World Seek Expanded Use of Psychedelics as... - September 16th, 2021
- Psilocybin Transdermal Patches Could Be The Next Big Thing In Psychedelics - Forbes - September 1st, 2021
- Psychedelics are getting closer to approval, but the market may not be ready - FierceBiotech - August 22nd, 2021
- At-Home Genetic Testing Cant Tell You If Youre Going to Have a Bad Trip - VICE - August 22nd, 2021
- Past, Present & Future of Psychedelic-Assisted Therapy: A New Dawn for Mental Health and Neuroscience - cmc.edu - August 22nd, 2021
- Researchers breaking away from the central dogma of depression - STAT - STAT - August 22nd, 2021
- When did humans start experimenting with alcohol and drugs? - EL PAS in English - August 22nd, 2021
- Origin Therapeutics Will Invest $5.1M In Psychedelics Startups - Yahoo Finance - August 14th, 2021